Research findings into investment by international pharmaceutical companies in Russia will be discussed on the first day of the St. Petersburg International Economic Forum. This dialogue is the continued round table discussion "Healthcare Investment in 2006-2016: Error Check" that took place this year at the Gaidar Forum.

Experts will learn updated data from a survey of foreign companies investing in the healthcare and pharmaceutical industry of the Russian Federation. The discourse topic will be fundamental barriers and challenges preventing from decision-making in projects related to these areas.

Among them the moderators of the session, in particular, highlighted the need to expand the procurement mechanism to ensure demand for drugs during the payback period of localization projects, as well as compulsory licensing. In addition, the focus will be patent infringements through registration of prices for reproduced drugs before the expiry of original drug patents. The changing rules for registering maximum sale prices and setting limited profitability of 30% are important.

Representatives of the Ministry of Health, the Ministry of Industry and Trade, the Federal Antimonopoly Service, regional authorities and pharmaceutical companies joined the discussion organized by EY and the Foreign Investment Advisory Council.